• Hsin-Fu Lee, Lai-Chu See, Yi-Hsin Chan, Yung-Hsin Yeh, Lung-Sheng Wu, Jia-Rou Liu, Hui-Tzu Tu, Chun-Li Wang, Chi-Tai Kuo, and Shang-Hung Chang.
• Department of Cardiology, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan.
• Intern Med J. 2018 Sep 1; 48 (9): 1123-1132.

BackgroundThe association between the use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) and mortality in end-stage renal disease (ESRD) patients lacks sufficient evidence.AimTo investigate the efficacy of ACEI and ARB in ESRD patients.MethodsThis nationwide retrospective cohort study using data from the Taiwan National Health Insurance Research Database enrolled ESRD patients from January 1997 to December 2011. Propensity score matching provided two study groups (ACEI/ARB users vs non-users), balanced in sample size, with similar comorbidities and prescriptions. These patients were followed up from the first date of receiving dialysis until mortality, 5 years or 31 December 2013 (whichever came first). We analysed the association of the use of ACEI or ARB with cardiovascular (CV) death and all-cause mortality in patients with ESRD using the Kaplan-Meier method and time-dependent Cox models, with a robust sandwich variance method.ResultsAfter propensity score matching, all characteristics of the user of ACEI or ARB (n = 17 280) and non-user (n = 17 280) groups were appropriately balanced (P > 0.05). In the Cox proportional hazards model, the user group exhibited lower CV death and all-cause mortality with adjusted hazard ratios and 95% CI of 0.58 (0.55-0.62) and 0.47 (0.46-0.49) than the non-user group did. Furthermore, the association of ACEI/ARB use with low mortality risk was observed in all examined subgroups.ConclusionIn this large-scale, population-based cohort study, ESRD patients using ACEI/ARB had a lower risk of CV death and all-cause mortality than non-users did.© 2018 Royal Australasian College of Physicians.

24 keywords...

hide…